Press

Core One Labs’ Akome Achieves Another Milestone in Development of its Psychedelic Drug Formulas and Announces Positive Results from Neuro-Pharmacokinetics Studies

Aug 22 • 3 min read

Core One Labs Inc. (CSE: COOL | OTCQB: CLABF | Frankfurt: LD6 | WKN: A3CSSU) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. through its formalized research agreement with Fundación Medina in Granada, Spain has received very encouraging results from pharmacokinetics studies currently underway. The study results represent another significant milestone in…

PharmAla Biotech to supply Major Australian Research Institute with LaNeo™ MDMA for Phase 3 Clinical Trial

Aug 22 • 2 min read

PharmAla Biotech is proud to have been selected as the MDMA manufacturing partner for the a major Australian Research institute’s Phase 3 clinical trial. With the product release of PharmAla’s LaNeo™ MDMA earlier this month now complete, researchers across the globe now have a new option to drive their research. “Having completed our value chain for…

HAVN Life Announces the close of the first tranche of its previously announced Financing Commitment by Alpha Blue Ocean and Warrant Amendments‎ and the Issuance of Shares for Debt

Aug 19 • 9 min read

HAVN Life Sciences Inc. (CSE: HAVN | OTC: HAVLF | FSE: 5NP) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce that it has closed the initial tranche of its financing commitment by Alpha Blue Ocean that was previously announced on July 21, 2022. The Company intends…

Small Pharma Announces TSXV Approval of Normal Course Issuer Bid

Aug 19 • 3 min read

Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that the TSX Venture Exchange has accepted the Company’s application for its normal course issuer bid for up to five million common shares in the capital of the Company, representing 1.55% of the issued…

Bright Minds Biosciences Comments on Recent Trading Activity

Aug 19 • 2 min read

Bright Minds Biosciences (Nasdaq: DRUG | CSE: DRUG), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, is issuing this news release in response to a request by the Investment Industry Regulatory Organization of Canada to comment on recent trading activity of its stock. The Company is…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441